Physician profile
Robert Hammill Lee
NPI 1770529323
$6,109.64
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $1,377 · 2021: $1,633 · 2022: $1,901 · 2023: $19.41 · 2024: $15.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,131.09 | 2019-2022 | |
| Preventric Diagnostics, INC. | $469.34 | 2022 | |
| Abbvie INC. | $446.25 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $404.72 | 2019-2022 | |
| Pfizer INC. | $369.89 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $306.21 | 2019-2022 | |
| Lilly USA, LLC | $266.83 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $265.82 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.39 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $177.87 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.00 | 2021-2024 | |
| Allergan, INC. | $169.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $161.41 | 2019-2022 | |
| Glaxosmithkline, LLC. | $119.75 | 2019-2022 | |
| Amarin Pharma, INC. | $118.97 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.